Universal Beteiligungs und Servicegesellschaft mbH Has $3.54 Million Stake in Inspire Medical Systems, Inc. $INSP

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH boosted its stake in Inspire Medical Systems by 990.1% in Q4, now owning 38,404 shares worth about $3.54 million (≈0.13% of the company).
• Inspire reported strong quarterly results — $1.65 EPS vs. $0.69 consensus and revenue of $269.1M (up 12.2% YoY) — while the company trades at a market cap of $1.53B and a PE of 10.7.
• Analysts are largely cautious (13 Holds, 5 Buys, 1 Sell) with an average price target of $101.41, well above the recent share price near $53 and its 50-/200-day moving averages of $56.81 and $79.79.

Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 990.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 38,404 shares of the company's stock after buying an additional 34,881 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned 0.13% of Inspire Medical Systems worth $3,542,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in INSP. Deerfield Management Company L.P. lifted its position in shares of Inspire Medical Systems by 648.4% in the third quarter. Deerfield Management Company L.P. now owns 1,047,694 shares of the company's stock valued at $77,739,000 after buying an additional 907,694 shares during the last quarter. Balyasny Asset Management L.P. lifted its holdings in Inspire Medical Systems by 16,504.3% during the 3rd quarter. Balyasny Asset Management L.P. now owns 614,359 shares of the company's stock worth $45,585,000 after purchasing an additional 610,659 shares during the last quarter. William Blair Investment Management LLC lifted its holdings in Inspire Medical Systems by 68.7% during the 3rd quarter. William Blair Investment Management LLC now owns 1,297,573 shares of the company's stock worth $96,280,000 after purchasing an additional 528,404 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in Inspire Medical Systems by 773.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 522,180 shares of the company's stock worth $38,746,000 after purchasing an additional 462,412 shares during the last quarter. Finally, Braidwell LP lifted its holdings in Inspire Medical Systems by 69.2% during the 3rd quarter. Braidwell LP now owns 883,747 shares of the company's stock worth $65,574,000 after purchasing an additional 361,337 shares during the last quarter. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Price Performance

Inspire Medical Systems stock opened at $53.30 on Thursday. The stock's fifty day moving average price is $56.81 and its two-hundred day moving average price is $79.79. Inspire Medical Systems, Inc. has a one year low of $48.30 and a one year high of $163.35. The firm has a market cap of $1.53 billion, a PE ratio of 10.70, a price-to-earnings-growth ratio of 2.84 and a beta of 0.86.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Wednesday, February 11th. The company reported $1.65 EPS for the quarter, topping analysts' consensus estimates of $0.69 by $0.96. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The firm had revenue of $269.08 million for the quarter, compared to analyst estimates of $264.02 million. During the same quarter last year, the company earned $1.15 EPS. The company's revenue was up 12.2% on a year-over-year basis. Sell-side analysts expect that Inspire Medical Systems, Inc. will post 1.82 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on INSP. Truist Financial dropped their price target on Inspire Medical Systems from $70.00 to $64.00 and set a "hold" rating for the company in a report on Wednesday, April 15th. Morgan Stanley set a $60.00 price target on Inspire Medical Systems in a report on Wednesday, February 18th. Jefferies Financial Group dropped their price target on Inspire Medical Systems from $81.00 to $66.00 and set a "hold" rating for the company in a report on Thursday, February 12th. Zacks Research cut Inspire Medical Systems from a "strong-buy" rating to a "hold" rating in a report on Tuesday, April 14th. Finally, UBS Group set a $67.00 price target on Inspire Medical Systems in a report on Friday, February 13th. Five analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $101.41.

Inspire Medical Systems Company Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company's flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.